John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 30, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New Jersey on behalf of certain purchasers of shares of Agile Therapeutics Inc (NASDAQ:AGRX) over alleged Securities Laws Violations by Agile Therapeutics Inc.
Investors who purchased shares of Agile Therapeutics Inc. (NASDAQ:AGRX) have certain options and for certain investors there are short and strict deadlines running. Deadline: March 7, 2017. NASDAQ: AGRX investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants allegedly failed to disclose that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards, that over half of patients in its “Secure” Phase 3 Study discontinued the study early, that the Twirla patch therefore allegedly had a slight chance of FDA approval, and that, as a result of the foregoing, Defendants’ statements about Agile Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 3, 2017, Agile Therapeutics Inc. announced results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet reported that almost 2% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression."
Those who purchased Agile Therapeutics Inc (NASDAQ:AGRX) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
